Impact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherence

Persistent Link:
http://hdl.handle.net/10150/614015
Title:
Impact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherence
Author:
Russell, Kathy; Slack, Marion; Cooley, Janet; Mathews, Kelly
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2016
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Objectives: Patient medication adherence is a basic requirement for treating chronic myelogenous leukemia (CML) with oral tyrosine kinase inhibitors (TKIs). When imatinib adherence rates are less than 80 or 90 percent, major and complete molecular responses, respectively, do not happen. The purpose of this study was to determine the effect of a real-time medication monitoring (RTMM) reminder system adherence program on the medication possession ratio (MPR). Methods: This analytic study was a retrospective cohort study and used data extracted from chart reviews for patients who received services from 2011 to 2015. It was approved by the Institutional Review Board. The study consisted of an intervention group and a control group (50 patients each). MPRs, demographic, descriptive, and categorical variables were summarized using means, standard deviations (SD), and frequencies/percentages. Results: The study population consisted of adult patients (mean age=62.2, SD=2.7, 50% male) treated by Avella Specialty Pharmacy who received imatinib or nilotinib as treatment for CML, gastrointestinal stromal tumors (GIST), or a similar positive Philadelphia chromosome cancer. Only 4% of patients in the intervention group had an < 85% MPR, compared to 46% in the control group (p < 0.001). Conclusions: In those patients who had an MPR of ≥ 85%, the difference between the groups was statistically significant. As past studies have shown, adherence rates greater than 90% have a higher likelihood of a major or complete molecular response and a greatly reduced risk of disease progression.
Description:
Class of 2016 Abstract
Keywords:
pharmacy-based; oral chemotherapy; patient adherence; chronic myelogenous leukemia (CML); oral tyrosine kinase inhibitors (TKIs); real-time medication monitoring (RTMM)
Advisor:
Slack, Marion; Cooley, Janet; Mathews, Kelly

Full metadata record

DC FieldValue Language
dc.contributor.advisorSlack, Marionen
dc.contributor.advisorCooley, Janeten
dc.contributor.advisorMathews, Kellyen
dc.contributor.authorRussell, Kathyen
dc.contributor.authorSlack, Marionen
dc.contributor.authorCooley, Janeten
dc.contributor.authorMathews, Kellyen
dc.date.accessioned2016-06-21T21:55:23Z-
dc.date.available2016-06-21T21:55:23Z-
dc.date.issued2016-
dc.identifier.urihttp://hdl.handle.net/10150/614015-
dc.descriptionClass of 2016 Abstracten
dc.description.abstractObjectives: Patient medication adherence is a basic requirement for treating chronic myelogenous leukemia (CML) with oral tyrosine kinase inhibitors (TKIs). When imatinib adherence rates are less than 80 or 90 percent, major and complete molecular responses, respectively, do not happen. The purpose of this study was to determine the effect of a real-time medication monitoring (RTMM) reminder system adherence program on the medication possession ratio (MPR). Methods: This analytic study was a retrospective cohort study and used data extracted from chart reviews for patients who received services from 2011 to 2015. It was approved by the Institutional Review Board. The study consisted of an intervention group and a control group (50 patients each). MPRs, demographic, descriptive, and categorical variables were summarized using means, standard deviations (SD), and frequencies/percentages. Results: The study population consisted of adult patients (mean age=62.2, SD=2.7, 50% male) treated by Avella Specialty Pharmacy who received imatinib or nilotinib as treatment for CML, gastrointestinal stromal tumors (GIST), or a similar positive Philadelphia chromosome cancer. Only 4% of patients in the intervention group had an < 85% MPR, compared to 46% in the control group (p < 0.001). Conclusions: In those patients who had an MPR of ≥ 85%, the difference between the groups was statistically significant. As past studies have shown, adherence rates greater than 90% have a higher likelihood of a major or complete molecular response and a greatly reduced risk of disease progression.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectpharmacy-baseden
dc.subjectoral chemotherapyen
dc.subjectpatient adherenceen
dc.subjectchronic myelogenous leukemia (CML)en
dc.subjectoral tyrosine kinase inhibitors (TKIs)en
dc.subjectreal-time medication monitoring (RTMM)en
dc.titleImpact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherenceen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.